Status:
UNKNOWN
The Benefit of Add On DLBS1033 for Ischemic Stroke Patient
Lead Sponsor:
Duta Wacana Christian University
Collaborating Sponsors:
Dexa Laboratories Of Biomolecular Science
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Stroke is one of the most common non-communicable diseases worldwide. It is the leading cause of morbidity and mortality in many countries. Stroke is broadly classified into ischemic and hemorrhagic ...
Detailed Description
This was randomized, controlled, open-label, study from the period of April 2020 - August 2020 at Bethesda Hospital, Yogyakarta, Indonesia. There were 180 acute ischemic stroke patients who fulfilled...
Eligibility Criteria
Inclusion
- Male or female
- Adult age (\>18 years old)
- Diagnosed with acute ischemic stroke for the first time
- The onset is \<24 hours
- Not a referral patient
- GCS score of 15 (fully alert)
- Mild to moderate scores on NIHSS
Exclusion
- Subjects known to have hypersensitivity to DLBS1033
- Participated in other studies for the past 1 month
- Not competent enough in giving approval and answering questionnaires
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2020
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04425590
Start Date
April 1 2020
End Date
August 1 2020
Last Update
June 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bethesda Hospital Yogyakarta
Yogyakarta, Special Region of Yogyakarta, Indonesia, 55224